Jemincare
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 2 | Voltage-gated sodium channel NaV1.8Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Est. primary completion 2027-12-31 · NCT07242274 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.